From MIT News: Predictions from the OncoNPC model could enable doctors to choose targeted treatments for difficult-to-treat tumors. For a small percentage of cancer patients, doctors are unable to determine where their cancer originated....

PathAI: Latest research underscores advantages of digital tools at scale to enhance tumor microenvironment and biomarker understanding in non-small cell lung cancer and renal cell carcinoma BOSTON, Mass., April 11, 2023 /PRNewswire/...

PathAI PathExplore™ panel will empower oncology drug developers with improved tumor microenvironment spatial characterization from H&E, propelling a new phase of precision medicine. BOSTON, April 4, 2023 /PRNewswire/ -- PathAI, a...

Andy Beck of PathAI: AI will continue to get better over time. Systems are continually improving and will be considerably more advanced looking ahead just five years from now. This expectation of progress gives us in the AI industry optimism...

PathAI: Part of Multi-year Partnership Focusing on Drug Development in NASH and Oncology BOSTON, March 30, 2023 /PRNewswire/ -- PathAI, a leading provider of AI-powered pathology, today announced its partnership with GSK...

WHITE PLAINS, N.Y., Feb. 27, 2023 /PRNewswire/ -- Clarapath, a robotics company aimed at catalyzing change in the way pathology laboratories process human and animal tissue, today announced the acquisition of Mountain View,...